ERBB2 and breast carcinoma: A study found that a high proportion of TIL (>50%) in initial biopsies was associated with higher rates of pCR (odds ratio of 6.49; p < 0.001) in HER2-positive breast cancer treated with taxanes-cyclophosphamide-trastuzumab-pertuzumab regimens [52].